Katono Ken, Sato Yuichi, Kobayashi Makoto, Nagashio Ryo, Ryuge Shinichiro, Igawa Satoshi, Ichinoe Masaaki, Murakumo Yoshiki, Saegusa Makoto, Masuda Noriyuki
Department of Respiratory Medicine, School of Medicine.
Department of Molecular Diagnostics, School of Allied Health Sciences.
Onco Targets Ther. 2017 Nov 2;10:5273-5279. doi: 10.2147/OTT.S145072. eCollection 2017.
Although cisplatin-based adjuvant chemotherapy improves the survival of patients with resected non-small-cell lung cancer, not all patients show a survival benefit, and some patients experience severe toxicity. Therefore, identifying biomarkers is important for selecting subgroups of patients who may show improved survival with platinum-based adjuvant chemotherapy. S100A16 is thought to play key roles during different steps of tumor progression. The aim of this study was to evaluate the use of S100A16 expression as a prognostic marker in patients with completely resected lung adenocarcinoma receiving platinum-based adjuvant chemotherapy.
S100A16 expression was immunohistochemically studied in 65 consecutive lung adenocarcinoma patients who underwent complete resection and received platinum-based adjuvant chemotherapy. Kaplan-Meier survival analysis and Cox proportional hazards models were used to estimate the effect of S100A16 expression on disease-free survival (DFS) and overall survival (OS).
S100A16 expression was detected in 26 of the 65 (40.0%) lung adenocarcinoma patients. Although S100A16 expression was not correlated with DFS (=0.062), it was significantly correlated with OS (=0.009). In addition, multivariable analysis revealed that S100A16 expression independently predicted a poorer survival (HR =4.79; 95% CI =1.87-12.23; =0.001).
The present study revealed that S100A16 is a promising candidate as a prognostic marker for platinum-based adjuvant chemotherapy in resected lung adenocarcinoma. A further large-scale study is needed to confirm the present results.
尽管基于顺铂的辅助化疗可提高非小细胞肺癌切除患者的生存率，但并非所有患者都能从中获益，且部分患者会出现严重毒性。因此，识别生物标志物对于选择可能从铂类辅助化疗中提高生存率的患者亚组很重要。S100A16被认为在肿瘤进展的不同阶段发挥关键作用。本研究的目的是评估S100A16表达作为接受铂类辅助化疗的完全切除肺腺癌患者预后标志物的应用价值。
对65例连续的肺腺癌患者进行免疫组织化学研究，这些患者均接受了完全切除并接受了铂类辅助化疗。采用Kaplan-Meier生存分析和Cox比例风险模型来评估S100A16表达对无病生存期（DFS）和总生存期（OS）的影响。
65例肺腺癌患者中有26例（40.0%）检测到S100A16表达。尽管S100A16表达与DFS无关（=0.062），但与OS显著相关（=0.009）。此外，多变量分析显示S100A16表达独立预测较差的生存率（HR =4.79；95% CI =1.87-12.23；=0.001）。
本研究表明S100A16有望作为切除肺腺癌铂类辅助化疗的预后标志物。需要进一步的大规模研究来证实本研究结果。
